ARE Patent Alert: The Federal Circuit Invalidates Pharmaceutical Claims Based on Indefiniteness

A recent decision by the Federal Circuit highlights the importance of word selection and consistency in drafting patent applications.    In IBSA Institut BioChimique, S.A., Altergon, S.A., IBSA Pharma Inc., v. Teva Pharmaceuticals USA, Inc., Slip Op. 2019-2400 (Fed. Cir. July 31, 2020), the Federal Circuit affirmed a lower court’s holding that the asserted claims […]